P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability

2018 ◽  
Vol 15 (11) ◽  
pp. 5124-5134 ◽  
Author(s):  
Stéphanie van Hoppe ◽  
Johannes J. M. Rood ◽  
Levi Buil ◽  
Els Wagenaar ◽  
Rolf W. Sparidans ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Oral Bioavailability ◽  
Kinase Inhibitor ◽  
Bruton’S Tyrosine Kinase ◽  
Cytochrome P450 3A ◽  
Bruton's Tyrosine Kinase ◽  
Brain Penetration ◽  
P Glycoprotein

scholarly journals Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

Blood ◽  
2017 ◽  
Vol 129 (20) ◽  
pp. 2808-2810 ◽  
Author(s):  
Harriet S. Walter ◽  
Sandrine Jayne ◽  
Simon A. Rule ◽  
Guillaume Cartron ◽  
Franck Morschhauser ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document